code,parent_code,name,possibility,medical_reasoning
"3A00.0,3A00,Acquired iron deficiency anaemia due to blood loss",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and iron levels (LBXSIR), which are essential for screening and assessing iron deficiency anemia. These features can help identify anemia and suggest iron deficiency, thus enabling a probabilistic model for the disease."
"3A00.01,3A00,Chronic posthaemorrhagic anaemia",,,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW) are available, which are essential for screening chronic posthaemorrhagic anemia. These features can help assess anemia severity and differentiate it from other types of anemia."
"3A00.0Z,3A00,""Acquired iron deficiency anaemia due to blood loss, unspecified""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and iron levels (LBXSIR), which are essential for screening and assessing iron deficiency anemia. These features can help identify anemia and suggest iron deficiency, thus enabling a probabilistic model for the disease."
"3A00.1,3A00,Acquired iron deficiency anaemia due to low intake",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and iron levels (LBXIR), which are essential for screening and assessing iron deficiency anemia. These features can help establish a reasonable sensitivity and specificity for identifying individuals at risk of acquired iron deficiency anemia due to low intake."
"3A00.2,3A00,Acquired iron deficiency anaemia due to decreased absorption",,,Possible,"Key features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and mean cell volume (LBXMCVSI) are available, which are essential for screening iron deficiency anemia. Additionally, iron levels (LBXSIR) can help assess iron status, supporting the likelihood assessment."
"3A00.3,3A00,Acquired iron deficiency anaemia due to increased requirement",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and iron levels (LBXSIR), which are essential for screening and assessing iron deficiency anemia. These features can help identify low hemoglobin levels and low iron stores, which are indicative of acquired iron deficiency anemia due to increased requirements."
"3A00.Y,3A00,Other specified iron deficiency anaemia",,,Possible,"Key features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and iron levels (LBXSIR) are available, which are essential for screening iron deficiency anemia. These features can help establish a reasonable sensitivity and specificity for the condition."
"3A00.Z,3A00,""Iron deficiency anaemia, unspecified""",,,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and iron levels (LBXSIR) are available, which are essential for screening iron deficiency anemia."
"3A01.0,3A01,Hereditary vitamin B12 deficiency anaemia",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia indicative of vitamin B12 deficiency. However, the absence of direct measures of vitamin B12 levels or methylmalonic acid (MMA) limits the specificity of the screening."
"3A01.1,3A01,Neonatal vitamin B12 deficiency anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. However, the absence of vitamin B12 levels or related metabolic markers limits the specificity for diagnosing vitamin B12 deficiency anemia. Nonetheless, the hematological features can still provide a reasonable screening framework for anemia, which may include vitamin B12 deficiency as a differential diagnosis."
"3A01.2,3A01,Vitamin B12 deficiency anaemia due to low intake",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify macrocytic anemia typically associated with Vitamin B12 deficiency. Additionally, demographic features like age (RIDAGEYR) and gender (RIAGENDR) can assist in stratifying risk. However, the absence of direct measures of Vitamin B12 levels or methylmalonic acid limits the specificity of the screening."
"3A01.3,3A01,Vitamin B12 deficiency anaemia due to intrinsic factor deficiency",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify macrocytic anemia typically associated with Vitamin B12 deficiency. However, the absence of direct measures of Vitamin B12 levels or intrinsic factor status limits the specificity of the screening. Nonetheless, the hematological features can still provide a reasonable basis for screening and triaging patients for further evaluation."
"3A01.30,3A01,Pernicious anaemia",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia typical of pernicious anemia. However, the absence of vitamin B12 levels or intrinsic factor antibodies limits definitive screening."
"3A01.3Y,3A01,Other specified vitamin B12 deficiency anaemia due to intrinsic factor deficiency",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify macrocytic anemia typically associated with vitamin B12 deficiency. However, the absence of direct measures of vitamin B12 levels or intrinsic factor status limits the specificity of the screening. Nonetheless, the combination of these hematological features can provide a reasonable basis for screening and likelihood assessment."
"3A01.4,3A01,Vitamin B12 deficiency anaemia due to intestinal disease",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can indicate macrocytic anemia typically associated with Vitamin B12 deficiency. Additionally, the presence of iron levels (LBXIR) can help differentiate between types of anemia. However, the absence of specific markers for Vitamin B12 levels (e.g., serum B12 or methylmalonic acid) limits the precision of the screening."
"3A01.5,3A01,Drug-induced vitamin B12 deficiency anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. Additionally, the presence of demographic data (age, gender) allows for stratification of risk. However, the absence of vitamin B12 levels or related metabolic markers limits the specificity of the screening for drug-induced vitamin B12 deficiency anemia. Nonetheless, the hematological features can still provide a reasonable basis for assessing anemia likelihood."
"3A01.Y,3A01,Other specified megaloblastic anaemia due to vitamin B12 deficiency",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), mean cell volume (LBXMCVSI), and red blood cell count (LBXRBCSI) are available, which can indicate megaloblastic anemia. However, the absence of vitamin B12 levels or methylmalonic acid, which are critical for confirming vitamin B12 deficiency, limits the specificity of the assessment. Nonetheless, the available features can still provide a reasonable screening framework for identifying potential cases of megaloblastic anemia."
"3A01.Z,3A01,""Megaloblastic anaemia due to vitamin B12 deficiency, unspecified,""",,,Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify megaloblastic anemia. However, the absence of vitamin B12 levels or methylmalonic acid, which are critical for definitive diagnosis, limits the specificity of the screening. Nonetheless, the available features can still provide a reasonable basis for screening and likelihood assessment."
"3A02.0,3A02,Hereditary folate deficiency anaemia",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia indicative of folate deficiency. However, the absence of direct folate level measurements limits specificity."
"3A02.1,3A02,Folate deficiency anaemia due to low intake",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify anemia and suggest folate deficiency. However, direct measurement of folate levels is not included, which is essential for definitive diagnosis. Nonetheless, the available features can still provide a reasonable screening framework for assessing likelihood based on anemia indicators."
"3A02.2,3A02,Folate deficiency anaemia due to increased requirements",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. Additionally, demographic features like age (RIDAGEYR) and gender (RIAGENDR) can assist in stratifying risk. However, the absence of direct measures of folate levels or dietary intake limits the specificity of screening for folate deficiency anemia."
"3A02.3,3A02,Folate deficiency anaemia due to decreased intestinal absorption",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify anemia. Additionally, demographic features like age (RIDAGEYR) and gender (RIAGENDR) can assist in stratifying risk. However, the absence of direct measures of folate levels or specific absorption tests limits the precision of the screening."
"3A02.4,3A02,Drug-induced folate deficiency anaemia",,,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify anemia. Additionally, the presence of iron levels (LBXSI) can assist in differentiating between types of anemia, including drug-induced folate deficiency anemia. However, specific folate levels are not listed, which could limit the precision of the assessment."
"3A02.Y,3A02,Other specified folate deficiency anaemia",,,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia associated with folate deficiency. However, the absence of direct folate level measurements limits specificity."
"3A02.Z,3A02,""Folate deficiency anaemia, unspecified""",,,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia associated with folate deficiency. Additionally, demographic features like age (RIDAGEYR) and gender (RIAGENDR) can enhance the screening model. However, direct measurement of folate levels is missing, which is essential for definitive diagnosis. Nonetheless, the available features can still provide a reasonable screening framework."
"3A03.0,3A03,Hereditary orotic aciduria",,,Not Possible,"Key signals for hereditary orotic aciduria, such as orotic acid levels in urine or specific genetic markers, are not available in the listed features."
"3A03.1,3A03,Protein deficiency anaemia",,,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and total protein (LBXSTP) are available, which can help assess protein deficiency anemia. These features can provide sufficient data to evaluate anemia and its potential causes, allowing for a meaningful screening approach."
"3A03.2,3A03,Scorbutic anaemia",,,Possible,"Scorbutic anemia is primarily due to vitamin C deficiency, which can lead to anemia characterized by low hemoglobin and hematocrit levels. The available features include hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for assessing anemia. However, the absence of direct measures of vitamin C levels or dietary intake limits the ability to fully assess the likelihood of scorbutic anemia specifically. Nonetheless, the hematological features allow for a preliminary screening for anemia."
"3A03.3,3A03,Copper deficiency anaemia",,,Not Possible,"Key signals for screening copper deficiency anemia, such as serum copper levels and ceruloplasmin, are missing from the available features."
"3A03.4,3A03,Acquired other vitamin B deficiency anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. Additionally, iron levels (LBXIR) can assist in differentiating types of anemia, including vitamin B deficiency. However, specific vitamin B levels (e.g., B12, folate) are not listed, which limits the ability to confirm the deficiency directly. Nonetheless, the combination of hematological features allows for a reasonable screening approach for anemia, including acquired vitamin B deficiency."
"3A03.40,3A03,Acquired pyridoxine deficiency anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. Additionally, iron levels (LBXIR) can provide insights into nutritional deficiencies, including pyridoxine deficiency. However, direct measurement of pyridoxine levels is not available, which limits specificity. Nonetheless, the combination of these features allows for a reasonable screening approach for acquired pyridoxine deficiency anemia."
"3A03.41,3A03,Acquired riboflavin deficiency anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and mean cell volume (LBXMCVSI), which can help identify anemia. Additionally, iron levels (LBXIR) can provide insights into nutritional deficiencies, including riboflavin deficiency. However, specific riboflavin levels are not available, which limits direct assessment. Nonetheless, the combination of these hematological features allows for a reasonable screening approach for anemia, including acquired riboflavin deficiency."
"3A03.42,3A03,Acquired thiamine deficiency anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. Additionally, the presence of iron levels (LBXIR) can assist in differentiating types of anemia, including thiamine deficiency. However, direct measurement of thiamine levels is not available, which is a limitation for definitive diagnosis but does not preclude screening for anemia."
"3A03.4Y,3A03,Other specified acquired other vitamin B deficiency anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening anemia. Additionally, iron levels (LBXSI) can help differentiate between types of anemia, including those related to vitamin B deficiencies. However, specific vitamin B levels (e.g., B12, folate) are not listed, which limits the ability to confirm the deficiency type directly. Nonetheless, the existing features can still provide a reasonable basis for screening and assessing likelihood."
"3A03.5,3A03,Acquired vitamin A deficiency anaemia",,,Not Possible,"Key signals for assessing vitamin A deficiency anemia, such as serum retinol levels or dietary intake of vitamin A, are missing. The available hematological features do not provide sufficient information to screen for this specific deficiency."
"3A03.6,3A03,Acquired vitamin E deficiency anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and mean cell volume (LBXMCVSI), which can help identify anemia. Additionally, the presence of iron levels (LBXIR) can assist in differentiating types of anemia, including vitamin E deficiency anemia, as it can lead to hemolysis and other hematological changes. However, the absence of direct measures of vitamin E levels or specific markers for oxidative stress limits the precision of the screening."
"3A03.Y,3A03,Other and unspecified nutritional or metabolic anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for screening various types of anemia, including nutritional or metabolic anemia. Additionally, iron levels (LBXIR) can help assess iron deficiency anemia, a common cause of nutritional anemia."
"3A10.0,3A10,Haemolytic anaemias due to hexose monophosphate shunt or glutathione metabolism anomalies",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which can indicate hemolysis. Additionally, total bilirubin (LBXSTB) can help assess for hemolytic anemia. These features can be used to screen for hemolytic anemias due to metabolic anomalies."
"3A10.00,3A10,Haemolytic anaemia due to glucose-6-phosphate dehydrogenase deficiency",,,Possible,"Key features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and total bilirubin (LBXSTB) are available, which can indicate hemolysis and support screening for G6PD deficiency. However, the absence of G6PD enzyme activity testing limits definitive diagnosis but does not preclude screening based on hematological parameters."
"3A10.0Y,3A10,Other specified haemolytic anaemias due to hexose monophosphate shunt or glutathione metabolism anomalies",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which are essential for screening hemolytic anemias. Additionally, total bilirubin (LBXSTB) can indicate hemolysis. However, specific markers for hexose monophosphate shunt or glutathione metabolism anomalies are not included, which may limit specificity. Nonetheless, the combination of these features allows for a reasonable assessment of hemolytic anemia likelihood."
"3A10.0Z,3A10,""Haemolytic anaemias due to hexose monophosphate shunt or glutathione metabolism anomalies, unspecified""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which are essential for screening hemolytic anemias. Additionally, total bilirubin (LBXSTB) can indicate hemolysis. These features can help assess the likelihood of hemolytic anemia due to metabolic anomalies."
"3A10.1,3A10,Haemolytic anaemia due to adenosine deaminase excess",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which can indicate hemolysis. Additionally, total bilirubin (LBXSTB) can help assess for hemolytic anemia. These features can be used to build a probabilistic model for screening hemolytic anemia due to adenosine deaminase excess."
"3A10.2,3A10,Hereditary elliptocytosis",,,Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify the characteristic microcytic anemia and elliptocytosis associated with hereditary elliptocytosis."
"3A10.3,3A10,Familial pseudohyperkalaemia",,,Not Possible,"Familial pseudohyperkalaemia is characterized by elevated serum potassium levels without true hyperkalemia. Key features such as serum potassium measurements are missing, which are essential for screening and assessing this condition."
"3A10.Y,3A10,Other specified hereditary haemolytic anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which can indicate hemolysis. These features can help in screening for hereditary hemolytic anemia by assessing anemia severity and signs of hemolysis, thus allowing for a meaningful assessment of disease likelihood."
"3A10.Z,3A10,""Hereditary haemolytic anaemia, unspecified""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for screening hereditary hemolytic anemia. Additionally, lactate dehydrogenase (LBXSLDSI) and total bilirubin (LBXSTB) can indicate hemolysis. However, genetic testing or specific markers for certain types of hereditary hemolytic anemia are not available, but the existing features can still provide a reasonable basis for screening."
"3A20.0,3A20,""Autoimmune haemolytic anaemia, warm type""",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) are available, which can indicate hemolysis. Additionally, total bilirubin (LBXSTB) can help assess for hemolytic anemia. These features can be used to screen for autoimmune hemolytic anemia effectively."
"3A20.1,3A20,""Autoimmune haemolytic anaemia, cold type""",,,Possible,"Key features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) can indicate hemolysis, while total bilirubin (LBXSTB) can suggest increased breakdown of red blood cells, which are relevant for screening autoimmune hemolytic anemia."
"3A20.2,3A20,""Autoimmune haemolytic anaemia, mixed type, cold and warm""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which are critical for assessing hemolysis. Additionally, total bilirubin (LBXSTB) can indicate hemolytic processes. These features can help in screening for autoimmune hemolytic anemia by evaluating anemia and hemolysis indicators, thus allowing for a meaningful assessment of disease likelihood."
"3A20.3,3A20,Paroxysmal cold haemoglobinuria",,,Not Possible,"Paroxysmal cold hemoglobinuria is characterized by hemolysis due to cold exposure, typically requiring specific tests such as direct Coombs test, urine hemoglobin, and possibly cold agglutinins, which are not included in the available features."
"3A20.4,3A20,Alloimmune haemolytic anaemia",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) are available, which can indicate hemolysis. Additionally, total bilirubin (LBXSTB) can help assess for hemolytic anemia. However, the absence of direct markers for alloimmunity (e.g., direct Coombs test) limits specificity. Overall, a probabilistic model can be constructed using available features to screen for the likelihood of alloimmune hemolytic anemia."
"3A20.5,3A20,Evans syndrome",,,Possible,"Evans syndrome is characterized by autoimmune hemolytic anemia and thrombocytopenia. The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI), which can help identify abnormalities consistent with this syndrome. However, the absence of direct measures of autoantibodies or specific markers for hemolysis limits the specificity of the assessment. Nonetheless, the combination of these hematological features allows for a reasonable screening approach."
"3A20.Y,3A20,""Other specified acquired haemolytic anaemia, immune""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), total bilirubin (LBXSTB), and lactate dehydrogenase (LBXSLDSI), which are essential for screening hemolytic anemia. These features can help identify signs of hemolysis and anemia, thus allowing for a meaningful assessment of the likelihood of immune-mediated hemolytic anemia."
"3A21.0,3A21,Paroxysmal nocturnal haemoglobinuria",,,Not Possible,"Key features such as flow cytometry results for CD55 and CD59 expression, which are critical for diagnosing Paroxysmal Nocturnal Hemoglobinuria (PNH), are not available. Additionally, the absence of direct measures of hemolysis (e.g., haptoglobin, reticulocyte count) limits the ability to screen for this condition effectively."
"3A21.1,3A21,Microangiopathic haemolytic anaemia",,,Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), lactate dehydrogenase (LBXSLDSI), and total bilirubin (LBXSTB) are available, which can indicate hemolysis and anemia. These features can help in screening for microangiopathic hemolytic anemia by assessing for signs of hemolysis and anemia, thus allowing for a meaningful likelihood assessment."
"3A21.2,3A21,Haemolytic uraemic syndrome",,,Not Possible,"Key features such as renal function tests (e.g., creatinine clearance), specific markers for hemolysis (e.g., haptoglobin, reticulocyte count), and direct measures of thrombotic microangiopathy are missing, which are essential for screening hemolytic uremic syndrome."
"3A21.Y,3A21,""Other specified acquired haemolytic anaemia, non-immune""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which are essential for screening hemolytic anemia. Additionally, total bilirubin (LBXSTB) can indicate hemolysis. These features can help assess the likelihood of non-immune acquired hemolytic anemia effectively."
"3A50.0,3A50,Alpha thalassaemia",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red blood cell count (LBXRBCSI) are available, which can help identify microcytic anemia typical of alpha thalassemia. However, genetic testing or specific hemoglobin electrophoresis results are not available, which limits definitive diagnosis but does allow for screening based on hematological parameters."
"3A50.00,3A50,Mild alpha thalassaemia diseases",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening alpha thalassemia. These features can help identify microcytic anemia and other hematological abnormalities associated with the disease."
"3A50.01,3A50,Thalassaemic alpha-chain variants",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening thalassemia. These features can help identify microcytic anemia and abnormal red cell indices typically associated with alpha-chain variants of thalassemia."
"3A50.02,3A50,Haemoglobin H disease (- alpha / -- included)",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia and other abnormalities associated with Hemoglobin H disease."
"3A50.03,3A50,Homozygous or compound heterozygous alpha0 thalassaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening thalassemia. These features can help identify microcytic anemia and other hematological abnormalities associated with alpha thalassemia. However, genetic testing or specific hemoglobin electrophoresis results are not available, which limits definitive diagnosis but does not preclude screening."
"3A50.0Y,3A50,Other specified alpha thalassaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening alpha thalassemia. These features can help identify microcytic anemia and other hematological abnormalities associated with the disease. However, genetic testing or specific hemoglobin electrophoresis results, which are critical for definitive diagnosis, are not available."
"3A50.0Z,3A50,""Alpha thalassaemia, unspecified""",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia typical of alpha thalassemia."
"3A50.1,3A50,Alpha thalassaemia related syndromes",,,Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia typical of alpha thalassemia. These features can be used to screen for the disease effectively."
"3A50.2,3A50,Beta thalassaemia",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia typical of beta thalassemia. However, genetic testing or specific hemoglobin electrophoresis results are not available, which limits definitive diagnosis but does allow for screening based on hematological parameters."
"3A50.3,3A50,""Delta, delta-beta or gamma-delta-beta thalassaemia""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening thalassemia. These features can help identify microcytic anemia and abnormal red cell indices typically associated with thalassemia."
"3A50.4,3A50,Hereditary persistence of fetal haemoglobin",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and mean cell volume (LBXMCVSI), which can help identify elevated fetal hemoglobin levels indicative of hereditary persistence of fetal hemoglobin. However, genetic testing or specific fetal hemoglobin quantification is not available, but the existing features can still provide a reasonable basis for screening."
"3A50.Y,3A50,Other specified thalassaemias",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify thalassemia through microcytic anemia and other red blood cell indices. However, genetic testing or specific hemoglobin electrophoresis results, which are critical for definitive diagnosis, are not included."
"3A50.Z,3A50,""Thalassaemias, unspecified""",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify thalassemia through characteristic microcytic anemia and altered red cell indices."
"3A51.0,3A51,Sickle cell trait",,,Not Possible,"Screening for sickle cell trait typically requires hemoglobin electrophoresis or genetic testing to identify the presence of the HbS allele. The available features do not include any specific tests for hemoglobin variants or genetic markers, which are essential for accurate screening."
"3A51.1,3A51,Sickle cell disease without crisis",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and hematocrit (LBXHCT) are available, which can indicate anemia and other abnormalities associated with sickle cell disease. Additionally, age (RIDAGEYR) and gender (RIAGENDR) can help stratify risk. However, genetic testing or specific markers for sickle cell trait (e.g., hemoglobin electrophoresis) are not available, but the existing features can still provide a reasonable screening framework."
"3A51.2,3A51,Sickle cell disease with crisis",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) are available, which can indicate hemolysis and anemia associated with sickle cell disease. Additionally, the presence of age and gender data allows for stratification of risk. However, the absence of specific genetic markers or hemoglobin electrophoresis limits definitive diagnosis but does not preclude screening for likelihood assessment."
"3A51.3,3A51,Compound heterozygous sickling disorders without crisis",,,Not Possible,"Key signals for screening compound heterozygous sickling disorders, such as hemoglobin electrophoresis or genetic testing for sickle cell mutations, are missing. The available features do not provide sufficient specificity or sensitivity for effective screening."
"3A51.4,3A51,Compound heterozygous sickling disorders with crisis",,,Not Possible,"Key signals for screening sickle cell disorders, such as hemoglobin electrophoresis or genetic testing for hemoglobin variants, are missing. While some hematological parameters are available, they do not provide sufficient specificity or sensitivity for screening compound heterozygous sickling disorders."
"3A51.5,3A51,Haemoglobin C disease",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify abnormalities associated with Hemoglobin C disease."
"3A51.6,3A51,Haemoglobin D disease",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify abnormalities associated with Hemoglobin D disease."
"3A51.7,3A51,High affinity haemoglobin",,,Not Possible,"Key signals for high affinity hemoglobin disorders, such as specific hemoglobin electrophoresis results or genetic testing for hemoglobin variants, are not available in the listed features."
"3A51.8,3A51,Low affinity haemoglobin",,,Possible,"The available features include hemoglobin levels (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and mean cell volume (LBXMCVSI), which are critical for assessing low affinity hemoglobin conditions. These parameters can help identify abnormalities in red blood cell function and oxygen transport, thus enabling screening for low affinity hemoglobin disorders."
"3A51.9,3A51,Haemoglobin O disease",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and mean cell volume (LBXMCVSI) are available, which can help identify abnormalities associated with Hemoglobin O disease. These features can be used to screen for the disease by assessing hemoglobin variants and red cell indices, thus allowing for a meaningful assessment of disease likelihood."
"3A51.A,3A51,Haemoglobin E disease",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify abnormalities associated with Hemoglobin E disease."
"3A51.B,3A51,Haemoglobin C/beta thalassaemia compound heterozygosity",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify abnormalities associated with hemoglobin C/beta thalassemia. These features can be used to screen for the disease by assessing the presence of microcytic anemia and other hematological changes typical of thalassemia syndromes."
"3A51.Y,3A51,Other specified sickle cell disorders or other haemoglobinopathies",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening sickle cell disorders and other hemoglobinopathies. These features can help identify anemia and abnormal red blood cell morphology indicative of such conditions."
"3A51.Z,3A51,""Sickle cell disorders or other haemoglobinopathies, unspecified""",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW) are available, which can help identify abnormalities associated with sickle cell disorders. These features can be used to screen for anemia and abnormal hemoglobin profiles indicative of hemoglobinopathies."
"3A60.0,3A60,Congenital non-inherited pure red cell aplasia",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening pure red cell aplasia. These features can help identify significant anemia and abnormal red cell indices, which are indicative of the condition."
"3A60.1,3A60,Hereditary pure red cell aplasia",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening red cell aplasia. These features can help identify abnormalities in red blood cell production and support a probabilistic model for assessing the likelihood of hereditary pure red cell aplasia."
"3A60.Z,3A60,""Congenital pure red cell aplasia, unspecified""",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening congenital pure red cell aplasia. These features can help identify anemia and abnormal red cell indices, which are indicative of this condition."
"3A61.0,3A61,Acute acquired pure red cell aplasia",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening acute acquired pure red cell aplasia. These features can help identify significant anemia and changes in red cell production, which are indicative of the disease."
"3A61.1,3A61,Chronic acquired pure red cell aplasia",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening and assessing red cell aplasia. These features can help identify anemia and changes in red cell production, which are critical in evaluating chronic acquired pure red cell aplasia."
"3A61.Y,3A61,Other specified acquired pure red cell aplasia",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening pure red cell aplasia. These features can help identify anemia and changes in red blood cell production, which are critical for assessing this condition."
"3A61.Z,3A61,""Acquired pure red cell aplasia, unspecified""",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening and assessing anemia, including conditions like acquired pure red cell aplasia. These features can help identify significant deviations from normal values indicative of the disease."
"3A70.0,3A70,Congenital aplastic anaemia",,,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI), which can help identify cytopenias characteristic of congenital aplastic anemia. These features can be used to build a probabilistic model to assess the likelihood of the disease."
"3A70.1,3A70,Acquired aplastic anaemias",,,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI), which are essential for screening aplastic anemia. These features can help identify cytopenias characteristic of the disease, thus enabling a probabilistic model for screening."
"3A70.10,3A70,Drug-induced aplastic anaemia",,,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI), which can help identify cytopenias characteristic of drug-induced aplastic anemia. However, the absence of specific drug exposure history or genetic markers limits the assessment's precision."
"3A70.11,3A70,Aplastic anaemia due to other external agents",,,Possible,"Aplastic anemia can be screened using features such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI). These hematological parameters can indicate cytopenias characteristic of aplastic anemia. However, the absence of specific tests for bone marrow function or exposure history limits the assessment's precision."
"3A70.12,3A70,Idiopathic aplastic anaemia",,,Possible,"Key hematological features such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI) are available, which can help identify cytopenias characteristic of aplastic anemia. However, the absence of bone marrow analysis or specific genetic markers limits definitive diagnosis but does not preclude screening for likelihood assessment."
"3A70.1Y,3A70,Other specified acquired aplastic anaemias",,,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI), which can help identify cytopenias characteristic of aplastic anemia. These features can be used to screen for the likelihood of the disease by assessing peripheral blood counts and morphology, which are critical in diagnosing aplastic anemia."
"3A70.1Z,3A70,""Acquired aplastic anaemias, unspecified""",,,Possible,"Key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI) are available, which can help identify cytopenias characteristic of acquired aplastic anemia."
"3A70.Z,3A70,""Aplastic anaemia, unspecified""",,,Possible,"Aplastic anemia can be screened using features such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI). These hematological parameters can indicate cytopenias characteristic of aplastic anemia, allowing for a meaningful assessment of disease likelihood."
"3A71.0,3A71,Anaemia in neoplastic disease",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening anemia. Additionally, the presence of white blood cell count (LBXWBCSI) and other blood cell parameters can help assess the underlying neoplastic process. However, the absence of specific markers for neoplastic disease (e.g., tumor markers or imaging) limits the specificity of the assessment."
"3A71.1,3A71,Anaemia in chronic infectious diseases",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening anemia. Additionally, white blood cell count (LBXWBCSI) and differential counts can help assess underlying infectious processes contributing to chronic anemia."
"3A71.2,3A71,Anaemia in chronic kidney disease",,,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and red cell distribution width (LBXRDW) are available, which are essential for screening anemia. Additionally, creatinine (LBXSCR) is crucial for assessing kidney function, which is directly related to anemia in chronic kidney disease."
"3A71.Y,3A71,Anaemia due to other specified chronic disease",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for screening anemia. Additionally, the presence of white blood cell count (LBXWBCSI) and other blood cell parameters can help assess underlying chronic diseases contributing to anemia."
"3A71.Z,3A71,""Anaemia due to chronic disease, unspecified""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for screening anemia. Additionally, the presence of inflammatory markers like albumin (LBXSAL) can help assess chronic disease status, making it feasible to screen for anemia due to chronic disease."
"3A72.0,3A72,Congenital sideroblastic anaemias",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening and assessing anemia, including congenital sideroblastic anemias. However, the absence of specific iron studies (e.g., serum ferritin, transferrin saturation) limits the ability to fully characterize the iron metabolism abnormalities typically associated with this condition. Despite this, the existing features can still provide a reasonable basis for screening."
"3A72.00,3A72,Hereditary sideroblastic anaemias",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening and assessing anemia, including hereditary sideroblastic anemias. However, the absence of specific iron studies (e.g., serum ferritin, transferrin saturation) limits the ability to definitively diagnose the type of anemia, but screening for anemia is still feasible."
"3A72.01,3A72,Hereditary syndromic sideroblastic anaemia",,,Not Possible,"Key signals for hereditary syndromic sideroblastic anemia, such as specific iron studies (e.g., serum ferritin, transferrin saturation), genetic testing for mutations, and bone marrow examination for ringed sideroblasts, are missing. The available features do not provide sufficient information to screen or assess likelihood effectively."
"3A72.0Y,3A72,Other specified congenital sideroblastic anaemias",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening and assessing anemia, including congenital sideroblastic anemia. However, the absence of specific iron studies (e.g., serum ferritin, transferrin saturation) limits the ability to fully characterize the iron metabolism abnormalities typically associated with sideroblastic anemia. Despite this, the existing features can still provide a reasonable basis for screening."
"3A72.0Z,3A72,""Congenital sideroblastic anaemias, unspecified""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening and assessing anemia, including congenital sideroblastic anemia. However, the absence of specific iron studies (e.g., serum ferritin, transferrin saturation) limits the ability to fully characterize the iron metabolism abnormalities typically associated with this condition. Despite this limitation, the existing features can still provide a reasonable basis for screening."
"3A72.1,3A72,Acquired sideroblastic anaemias",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening anemia, including acquired sideroblastic anemias. However, the absence of specific iron studies (e.g., serum ferritin, transferrin saturation) limits the ability to definitively assess iron metabolism abnormalities typically associated with sideroblastic anemia. Despite this, the existing features can still provide a reasonable basis for initial screening and likelihood assessment."
"3A72.Z,3A72,""Sideroblastic anaemia, unspecified""",,,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify abnormalities associated with sideroblastic anemia. However, iron studies (e.g., serum iron, ferritin) are not listed, which are typically crucial for a definitive assessment of sideroblastic anemia. Despite this, the available features can still provide a reasonable basis for screening."
"3A80.0,3A80,Primary inherited erythrocytosis",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for screening erythrocytosis. These features can help identify elevated red cell mass indicative of primary inherited erythrocytosis."
"3A80.Y,3A80,Other specified congenital polycythaemia",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for screening polycythemia. These features can help identify elevated red cell mass indicative of congenital polycythemia."
"3A80.Z,3A80,""Congenital polycythaemia, unspecified""",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for screening polycythemia. These features can help identify elevated red cell mass indicative of congenital polycythemia."
"3A81.0,3A81,""Polycythaemia due to hypoxia, including high altitude""",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for identifying polycythemia. Additionally, demographic features like age (RIDAGEYR) and gender (RIAGENDR) can help stratify risk. However, the absence of direct measures of oxygen saturation or altitude exposure limits the assessment's specificity. Nonetheless, the hematological features allow for a reasonable screening approach for polycythemia due to hypoxia."
"3A81.1,3A81,Polycythaemia due to over-transfusion or blood doping",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for identifying polycythemia. These features can help assess the likelihood of polycythemia due to over-transfusion or blood doping, as they provide critical information on erythrocyte mass and oxygen-carrying capacity."
"3A81.2,3A81,Relative polycythaemia",,,Possible,"Relative polycythemia can be assessed using available features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are critical for evaluating erythrocytosis. These features allow for the identification of elevated red cell mass, a key indicator of the condition."
"3A81.Y,3A81,Other specified acquired polycythaemia",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for screening polycythemia. These features can help identify elevated red cell mass indicative of polycythemia, thus allowing for a meaningful assessment of disease likelihood."
"3A81.Z,3A81,""Acquired polycythaemia, unspecified""",,,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for screening polycythemia. These features can help identify elevated red cell mass indicative of acquired polycythemia."
"3A8Z,3A8Z,""Polycythaemia, unspecified""",,,Possible,"Key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT) are available, which are essential for screening polycythaemia. These features can help identify elevated red cell mass indicative of the condition."
"3A90,3A90,Anaemia due to acute disease",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and white blood cell count (LBXWBCSI), which are essential for screening anemia. These features can help identify acute disease-related anemia by assessing changes in these values, thus allowing for a meaningful screening process."
"3A91,3A91,Congenital methaemoglobinaemia",,,Not Possible,"Key signals for congenital methaemoglobinaemia, such as methemoglobin levels or specific genetic markers, are not included in the available features."
"3A92,3A92,Hereditary methaemoglobinaemia",,,Not Possible,"Key signals for hereditary methaemoglobinaemia, such as methemoglobin levels or specific genetic markers, are not included in the available features. The listed hematological parameters do not provide sufficient information to screen for this condition."
"3A93,3A93,Acquired methaemoglobinaemia",,,Not Possible,"Key signals for screening acquired methemoglobinemia, such as methemoglobin levels or specific exposure history (e.g., drugs or chemicals), are not included in the available features."
"3A94,3A94,Acute posthaemorrhagic anaemia",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for screening and assessing anemia. These features can help identify acute posthaemorrhagic anemia by indicating low hemoglobin levels and changes in red blood cell indices."
"3A9Y,3A9Y,Other specified anaemias or erythrocyte disorders",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening various anemias. These features can help assess the likelihood of anemia and differentiate between types, thus enabling a meaningful screening process."
"3A9Z,3A9Z,""Anaemias or other erythrocyte disorders, unspecified""",,,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for screening various anemias. These features can help assess erythrocyte disorders and provide a basis for further evaluation."
"3B10.0,3B10,Haemophilia A",,,Not Possible,"Key signals for screening Haemophilia A, such as factor VIII activity levels or specific genetic testing for mutations in the F8 gene, are not included in the available features."
"3B10.1,3B10,Hereditary factor VIII deficiency with anti-factor VIII inhibitor",,,Not Possible,"Key signals for screening hereditary factor VIII deficiency with anti-factor VIII inhibitor, such as specific factor VIII activity assays and inhibitor testing, are not available in the listed features."
"3B10.Y,3B10,Other specified hereditary factor VIII deficiency",,,Not Possible,"Key signals for screening hereditary factor VIII deficiency, such as specific factor VIII activity assays or genetic testing for mutations in the F8 gene, are not available in the listed features."
"3B10.Z,3B10,""Hereditary factor VIII deficiency, unspecified""",,,Not Possible,"Key signals for screening hereditary factor VIII deficiency, such as specific factor VIII activity levels or genetic testing for mutations in the F8 gene, are not available in the listed features."
"3B11.0,3B11,Haemophilia B",,,Not Possible,"Key signals for screening Haemophilia B, such as specific factor IX activity levels or genetic testing for mutations in the F9 gene, are not available in the listed features."
"3B11.Y,3B11,Other specified hereditary factor IX deficiency",,,Not Possible,"Key signals for screening hereditary factor IX deficiency, such as specific coagulation factor assays (e.g., factor IX activity), are missing. The available features do not include relevant hematological parameters or genetic testing necessary for effective screening."
"3B11.Z,3B11,""Hereditary factor IX deficiency, unspecified""",,,Not Possible,"Key signals for screening hereditary factor IX deficiency, such as specific coagulation factor assays (e.g., factor IX activity), are missing. The available features do not include relevant hematological parameters or genetic markers necessary for effective screening."
"3B12,3B12,Von Willebrand disease",,,Not Possible,"Von Willebrand disease screening typically requires specific tests for von Willebrand factor levels and activity, as well as factor VIII levels, which are not included in the available features. The listed hematological parameters do not provide sufficient information to assess the likelihood of this bleeding disorder."
"3B13,3B13,Haemophilia C",,,Not Possible,"Key signals for screening Haemophilia C, such as specific factor XI activity levels or genetic testing for mutations in the F11 gene, are not available in the listed features."
"3B14.0,3B14,Hereditary deficiency of factor I",,,Not Possible,"Key signals for screening hereditary deficiency of factor I, such as specific factor I activity assays or genetic testing, are not available in the listed features. The available hematological parameters do not provide sufficient information to assess this condition."
"3B14.1,3B14,Hereditary factor X deficiency",,,Not Possible,"Key signals for hereditary factor X deficiency, such as specific coagulation factor assays (e.g., factor X activity), are missing. The available features do not include any coagulation parameters necessary for screening or assessing bleeding disorders."
"3B14.2,3B14,Combined deficiency of vitamin K-dependent clotting factors",,,Not Possible,"Key signals for screening combined deficiency of vitamin K-dependent clotting factors, such as prothrombin time (PT) and specific vitamin K levels, are missing. The available features do not include coagulation parameters necessary for assessing this condition."
"3B14.Z,3B14,Other inherited coagulation factor deficiency with bleeding tendency, unspecified",,,Not Possible,"Key signals for inherited coagulation factor deficiencies, such as specific factor levels (e.g., Factor VIII, Factor IX), are missing. The available features do not include coagulation studies or specific bleeding disorder markers necessary for screening."
"3B15,3B15,Inherited coagulation factor deficiency without bleeding tendency",,,Not Possible,"Key signals for inherited coagulation factor deficiencies, such as specific factor assays (e.g., Factor VIII, Factor IX levels), are missing. The available features do not provide the necessary hematological parameters to assess coagulation factor levels or function."
"3B20,3B20,Disseminated intravascular coagulation",,,Not Possible,"Key signals for disseminated intravascular coagulation (DIC) such as fibrinogen levels, D-dimer, and specific coagulation factors are missing. The available features do not provide sufficient information to assess coagulation status or the presence of DIC."
"3B21.0,3B21,Haemorrhage due to thrombin inhibitor other than heparin",,,Not Possible,"Key signals such as specific coagulation parameters (e.g., thrombin time, anti-Xa levels) and clinical history of anticoagulant use are missing, which are essential for screening and assessing the likelihood of hemorrhage due to thrombin inhibitors."
"3B21.1,3B21,Haemorrhage due to factor Xa inhibitor",,,Not Possible,"Key signals for screening hemorrhage due to factor Xa inhibitors, such as specific coagulation tests (e.g., anti-Xa levels, PT/INR, aPTT), are missing. The available features do not provide sufficient information to assess bleeding risk or anticoagulation status."
"3B21.Y,3B21,Haemorrhagic disorder due to other specified circulating anticoagulants",,,Not Possible,"Key signals such as specific coagulation factor levels, presence of circulating anticoagulants, or specific tests for bleeding disorders are missing. The available features do not provide the necessary information to assess the likelihood of hemorrhagic disorders due to circulating anticoagulants."
"3B21.Z,3B21,Haemorrhagic disorder due to unspecified circulating anticoagulants",,,Not Possible,"Key signals for screening hemorrhagic disorders due to circulating anticoagulants, such as specific coagulation tests (e.g., PT, aPTT, specific inhibitor assays), are missing. The available features do not provide sufficient information to assess bleeding risk or anticoagulant presence."
"3B22,3B22,Acquired haemophilia",,,Not Possible,"Acquired hemophilia is characterized by the presence of inhibitors against clotting factors, particularly factor VIII. Key diagnostic features such as specific factor assays (e.g., factor VIII activity, inhibitor testing) and clinical bleeding history are essential for screening, which are not included in the available NHANES features."
"3B2Y,3B2Y,Other specified haemorrhagic diseases due to acquired coagulation factor defects",,,Not Possible,"Key signals for screening acquired coagulation factor defects, such as specific factor assays (e.g., Factor VIII, Factor IX levels) and functional assays (e.g., PT, aPTT), are missing. The available features do not provide sufficient information to assess coagulation status or factor deficiencies."
"3B50.0,3B50,Congenital alpha-2 antiplasmin deficiency",,,Not Possible,"Key signals for screening congenital alpha-2 antiplasmin deficiency, such as specific functional assays for alpha-2 antiplasmin levels or genetic testing, are missing. The available features do not provide the necessary information to assess the likelihood of this deficiency."
"3B50.1,3B50,Congenital plasminogen activator inhibitor type 1 deficiency",,,Not Possible,"Key signals for screening congenital plasminogen activator inhibitor type 1 deficiency, such as specific genetic testing or functional assays to measure plasminogen activator inhibitor levels, are not available in the listed features."
"3B50.Y,3B50,Other specified inherited fibrinolytic defects",,,Not Possible,"Key signals for inherited fibrinolytic defects, such as specific fibrinolytic enzyme activity assays (e.g., plasminogen levels, tissue plasminogen activator), are not available in the listed features."
"3B50.Z,3B50,Inherited fibrinolytic defects, unspecified",,,Not Possible,"Inherited fibrinolytic defects require specific assays to evaluate fibrinolytic activity, such as plasminogen levels, fibrinogen levels, and specific clotting factor assays, which are not included in the available features."
"3B51,3B51,Acquired fibrinolytic defects",,,Not Possible,"Acquired fibrinolytic defects require specific markers such as D-dimer levels or fibrinogen levels to assess fibrinolytic activity, which are not included in the available features."
"3B60.0,3B60,Hereditary vascular purpura",,,Not Possible,"Key signals for hereditary vascular purpura, such as specific genetic markers or tests for von Willebrand factor levels, are not included in the available features."
"3B60.1,3B60,Acquired vascular purpura",,,Not Possible,"Key signals for acquired vascular purpura, such as specific platelet function tests, coagulation profiles, or markers of vascular integrity, are missing. The available features do not provide sufficient information to assess the likelihood of this condition."
"3B61.0,3B61,Hereditary thrombophilia",,,Not Possible,"Key signals for hereditary thrombophilia, such as specific genetic markers (e.g., Factor V Leiden, Prothrombin mutation) and functional assays (e.g., activated protein C resistance), are not available in the listed features."
"3B61.00,3B61,Hyperhomocysteinaemia",,,Not Possible,"Hyperhomocysteinaemia is primarily assessed through serum homocysteine levels, which are not included in the available features. Without this key analyte, screening for the condition is not feasible."
"3B61.0Y,3B61,Other specified hereditary thrombophilia",,,Not Possible,"Key signals for hereditary thrombophilia, such as genetic markers (e.g., factor V Leiden, prothrombin mutation) and specific coagulation tests (e.g., protein C, protein S, antithrombin levels), are missing from the available features."
"3B61.0Z,3B61,Hereditary thrombophilia, unspecified",,,Not Possible,"Key signals for hereditary thrombophilia, such as genetic testing for specific mutations (e.g., Factor V Leiden, Prothrombin gene mutation) and functional assays (e.g., activated protein C resistance), are not available in the listed features."
"3B61.1,3B61,Acquired thrombophilia",,,Not Possible,"Key signals for acquired thrombophilia, such as specific coagulation factor levels (e.g., antiphospholipid antibodies, protein C, protein S, and antithrombin), are missing. The available features do not provide sufficient information to assess thrombotic risk or diagnose acquired thrombophilia."
"3B61.Y,3B61,Other specified thrombophilia",,,Not Possible,"Key signals for thrombophilia screening, such as genetic markers (e.g., Factor V Leiden, prothrombin mutation) and specific coagulation tests (e.g., antiphospholipid antibodies, protein C/S levels), are missing from the available features."
"3B61.Z,3B61,Thrombophilia, unspecified",,,Not Possible,"Key signals for thrombophilia screening, such as specific coagulation factor levels (e.g., Factor V Leiden, prothrombin mutation), antiphospholipid antibodies, and genetic testing, are not available in the listed features."
"3B62.0,3B62,Inherited qualitative platelet defects",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing qualitative platelet defects. These features can help identify abnormalities in platelet function and morphology, allowing for a meaningful screening approach."
"3B62.00,3B62,Alpha-granule diseases",,,Not Possible,"Key signals for alpha-granule diseases, such as specific platelet function tests or genetic markers, are missing. The available features do not provide sufficient information to screen or assess the likelihood of this disease."
"3B62.01,3B62,Inherited giant platelet disorder",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for screening inherited giant platelet disorders. These features can help identify abnormalities in platelet size and number, which are key indicators of the condition. Other hematological parameters such as white blood cell count and red blood cell indices may also provide supportive information."
"3B62.0Y,3B62,Other specified inherited qualitative platelet defects",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing qualitative platelet defects. These features can help identify abnormalities in platelet function and morphology, allowing for a meaningful screening approach for inherited qualitative platelet defects."
"3B62.0Z,3B62,Inherited qualitative platelet defects, unspecified",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing platelet function and identifying qualitative platelet defects. These features can help differentiate between normal and abnormal platelet function, thus enabling screening for inherited qualitative platelet defects."
"3B62.1,3B62,Bleeding diathesis due to thromboxane synthesis deficiency",,,Not Possible,"Key signals for screening thromboxane synthesis deficiency, such as platelet function tests (e.g., platelet aggregation studies) and specific biochemical markers related to thromboxane metabolism, are missing. The available features do not provide sufficient information to assess bleeding diathesis related to thromboxane synthesis."
"3B62.2,3B62,Isolated thrombocytopenia",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, the complete blood count parameters (e.g., white blood cell count, hemoglobin) can help rule out other hematological conditions. Thus, a screening model can be constructed to assess the likelihood of isolated thrombocytopenia."
"3B62.3,3B62,Dense granule disease",,,Not Possible,"Dense granule disease is a type of platelet storage pool disorder, which typically requires specific platelet function tests or genetic testing to diagnose. The available NHANES features do not include any specific tests for platelet function or granule content, making screening for this condition not feasible."
"3B62.4,3B62,Alpha-delta dense granule deficiency",,,Not Possible,"Alpha-delta dense granule deficiency is characterized by specific platelet function abnormalities and granule deficiencies, which require specialized tests such as platelet aggregation studies and electron microscopy for diagnosis. The available NHANES features do not include any specific tests for platelet function or granule content, making screening for this condition not feasible."
"3B62.5,3B62,Haemophagocytic syndrome associated with infection",,,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and monocyte percent (LBXMOPCT), which are critical for identifying hemophagocytic syndrome. These features can help assess the likelihood of the syndrome by indicating immune activation and cytopenias associated with infections. However, the absence of specific infectious markers or imaging studies limits the depth of assessment."
"3B62.Y,3B62,Other specified qualitative platelet defects",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are essential for assessing qualitative platelet defects. These features can help identify abnormalities in platelet function and morphology, allowing for a meaningful screening approach."
"3B62.Z,3B62,Qualitative platelet defects, unspecified",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are essential for assessing qualitative platelet defects. These features can help identify abnormalities in platelet function and morphology, allowing for a meaningful screening approach."
"3B63.0,3B63,Congenital thrombocytosis",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. These features can help identify elevated platelet levels indicative of congenital thrombocytosis, allowing for a meaningful screening approach."
"3B63.1,3B63,Acquired thrombocytosis",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) can help differentiate between reactive and primary causes of thrombocytosis, thus enabling a meaningful screening approach."
"3B63.10,3B63,Secondary thrombocytosis",,,Possible,"Secondary thrombocytosis can be assessed using the platelet count (LBXPLTSI) and other hematological parameters such as white blood cell count (LBXWBCSI) and red blood cell indices. These features allow for the identification of thrombocytosis and potential underlying causes, thus enabling screening and likelihood assessment."
"3B63.1Y,3B63,Other specified acquired thrombocytosis",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate the underlying causes of thrombocytosis, thus enabling a meaningful screening approach."
"3B63.1Z,3B63,""Acquired thrombocytosis, unspecified""",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) can help differentiate between reactive and primary causes of thrombocytosis. Other hematological parameters such as hemoglobin (LBXHGB) and red blood cell count (LBXRBCSI) can provide further context. No essential signals are missing for screening."
"3B63.Y,3B63,Other specified thrombocytosis",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) can help rule out other hematological conditions. These features can be used to build a probabilistic model for screening thrombocytosis."
"3B63.Z,3B63,""Thrombocytosis, unspecified""",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate causes of thrombocytosis, allowing for a meaningful screening approach."
"3B64.0,3B64,Congenital thrombocytopenia",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, the complete blood count parameters (e.g., white blood cell count, red blood cell count) can help rule out other hematological conditions. However, genetic testing or specific markers for congenital thrombocytopenia are not available, but the existing features allow for a reasonable screening approach."
"3B64.00,3B64,Congenital non-inherited thrombocytopenia",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. These features can help identify low platelet levels indicative of congenital non-inherited thrombocytopenia, allowing for a meaningful screening approach."
"3B64.01,3B64,Hereditary thrombocytopenia",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. These features can help identify low platelet levels indicative of hereditary thrombocytopenia, allowing for a meaningful screening approach."
"3B64.0Z,3B64,""Congenital thrombocytopenia, unspecified""",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. These features can help identify low platelet levels indicative of congenital thrombocytopenia, allowing for a meaningful screening approach."
"3B64.1,3B64,Acquired thrombocytopenia",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate causes of acquired thrombocytopenia, allowing for a meaningful screening approach."
"3B64.10,3B64,Immune thrombocytopenic purpura",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia in immune thrombocytopenic purpura (ITP). Additionally, white blood cell count (LBXWBCSI) and hemoglobin (LBXHGB) can help rule out other hematological conditions. These features can support a probabilistic model for screening ITP."
"3B64.11,3B64,Secondary thrombocytopenic purpura",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate causes of secondary thrombocytopenic purpura."
"3B64.12,3B64,Drug-induced thrombocytopenic purpura",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help evaluate the overall blood profile, supporting the screening for drug-induced thrombocytopenic purpura."
"3B64.13,3B64,Alloimmune thrombocytopenia",,,Not Possible,"Alloimmune thrombocytopenia requires specific tests for platelet antibodies or HLA typing, which are not included in the available features. The available features do not provide sufficient information to screen or assess the likelihood of this condition."
"3B64.14,3B64,Thrombotic thrombocytopenic purpura",,,Not Possible,"Key signals for thrombotic thrombocytopenic purpura (TTP) include ADAMTS13 activity and inhibitor levels, as well as specific clinical features like schistocytes on a blood smear. The available NHANES features do not include these essential tests or clinical indicators necessary for screening or likelihood assessment of TTP."
"3B64.1Y,3B64,Other specified acquired thrombocytopenia",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate causes of thrombocytopenia, thus enabling a meaningful screening approach."
"3B64.Z,3B64,""Thrombocytopenia, unspecified""",,,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate causes of thrombocytopenia, allowing for a meaningful screening approach."
"3B65,3B65,""Thrombotic microangiopathy, not elsewhere classified""",,,Not Possible,"Key signals for thrombotic microangiopathy, such as ADAMTS13 activity, anti-ADAMTS13 antibodies, and specific imaging studies, are missing. The available features do not provide sufficient information to screen or assess likelihood effectively."
"3B6Y,3B6Y,""Other specified coagulation defects, purpura or other haemorrhagic or related conditions""",,,Not Possible,"Key signals for screening coagulation defects, such as specific coagulation factor levels (e.g., factor VIII, factor IX), platelet function tests, or genetic markers, are missing. The available features do not provide sufficient information to assess coagulation status or bleeding risk effectively."
"3B6Z,3B6Z,""Coagulation defects, purpura or other haemorrhagic or related conditions, unspecified""",,,Possible,"The available features include key hematological parameters such as platelet count (LBXPLTSI), hemoglobin (LBXHGB), and white blood cell count (LBXWBCSI), which can help identify coagulation defects and related hemorrhagic conditions. However, the absence of specific coagulation factors or tests (e.g., PT, aPTT, or specific factor assays) limits the ability to fully characterize the coagulation status. Nonetheless, the existing features can still provide a reasonable basis for screening and assessing likelihood."
"3B80.0,3B80,Splenomegaly in storage diseases",,,Not Possible,"Key signals for screening splenomegaly in storage diseases, such as imaging studies (e.g., ultrasound, CT scan) and specific biochemical markers (e.g., enzyme levels related to specific storage diseases), are missing. The available features do not provide sufficient information to assess the likelihood of splenomegaly effectively."
"3B81.0,3B81,Tumour-like conditions of spleen",,,Not Possible,"Key diagnostic signals such as imaging studies (e.g., ultrasound, CT scan) or specific biomarkers related to splenic tumors are not available in the listed features, making screening for tumor-like conditions of the spleen infeasible."
"3B81.1,3B81,Postsurgical asplenia",,,Not Possible,"Key signals for assessing postsurgical asplenia, such as specific immunological markers (e.g., antibody responses, vaccination status) and clinical history of infections, are missing. The available features do not provide sufficient information to screen for the complications associated with asplenia."
"3B81.2,3B81,Atrophy of spleen",,,Not Possible,"Key signals for assessing splenic atrophy, such as imaging studies (e.g., ultrasound, CT scan) or specific biomarkers related to splenic function, are missing. The available hematological features do not provide sufficient information to screen for atrophy of the spleen."
"3B81.3,3B81,Nontraumatic laceration or rupture of spleen",,,Not Possible,"Key features such as imaging studies (e.g., ultrasound or CT scan) to identify splenic laceration or rupture are missing. Additionally, clinical signs of splenic injury (e.g., abdominal pain, hypotension) and specific laboratory tests (e.g., hemoglobin drop, lactate levels) that indicate splenic rupture are not available."
"3B81.4,3B81,Splenosis",,,Not Possible,"Key signals for diagnosing splenosis, such as imaging studies (e.g., ultrasound, CT scan) or specific genetic markers, are not available in the listed features. The available hematological parameters do not provide sufficient information to screen for splenosis effectively."
"3B81.5,3B81,Splenic cyst or pseudocyst",,,Not Possible,"Key imaging features (e.g., ultrasound or CT scans) necessary for diagnosing splenic cysts or pseudocysts are not available in the listed NHANES features."
"3B81.50,3B81,Pseudocyst of spleen",,,Not Possible,"Key imaging studies (e.g., ultrasound or CT scan) and specific laboratory tests (e.g., serum amylase or lipase) that are essential for diagnosing and screening pseudocysts of the spleen are not available in the listed features."
"3B81.51,3B81,Epithelial cyst of spleen",,,Not Possible,"Epithelial cysts of the spleen typically require imaging studies (e.g., ultrasound, CT scan) for diagnosis, which are not included in the available NHANES features. The listed features primarily assess hematological and biochemical parameters, which do not provide the necessary information for screening or likelihood assessment of this specific condition."
"3B81.5Y,3B81,Other specified splenic cyst",,,Not Possible,"Key imaging features (e.g., ultrasound or CT scans) necessary for diagnosing splenic cysts are missing, as well as specific laboratory markers that could indicate splenic pathology."
"3B81.5Z,3B81,""Splenic cyst, unspecified""",,,Not Possible,"Key imaging features (e.g., ultrasound or CT scans) necessary for diagnosing splenic cysts are not available, making screening for this condition infeasible."
"3B81.6,3B81,Infarction of spleen",,,Not Possible,"Key signals for screening splenic infarction, such as imaging studies (e.g., ultrasound or CT scan) and specific clinical history (e.g., sickle cell disease, thrombosis), are missing. The available hematological features do not provide sufficient information to assess the likelihood of splenic infarction."
"3B81.7,3B81,Infection of spleen",,,Not Possible,"Key signals for screening splenic infections, such as imaging studies (ultrasound, CT) or specific serological tests for pathogens, are missing. The available features primarily assess hematological parameters and do not provide sufficient information to screen for splenic infections."
"3B81.70,3B81,Acute septic splenitis",,,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and neutrophil percent (LBXNEPCT), which are critical for identifying infections and inflammatory processes like acute septic splenitis. These features can help establish a likelihood assessment for the disease based on typical laboratory findings associated with sepsis."
"3B81.71,3B81,Abscess of spleen",,,Not Possible,"Key diagnostic signals for splenic abscess, such as imaging studies (e.g., ultrasound, CT scan) and clinical signs of infection, are missing. While some hematological parameters (e.g., white blood cell count) may suggest infection, they are insufficient for screening or triaging splenic abscess specifically."
"3B81.7Y,3B81,Other specified infection of spleen",,,Not Possible,"Key signals for screening infections of the spleen, such as imaging studies (e.g., ultrasound, CT scan) or specific serological tests for pathogens, are missing. The available features primarily assess hematological parameters and do not provide sufficient information to screen for splenic infections."
"3B81.7Z,3B81,""Infection of spleen, unspecified""",,,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and monocyte percent (LBXMOPCT), which can indicate an infection. These features can help in screening for splenic infections by assessing the immune response and inflammatory markers, thus allowing for a probabilistic model to estimate disease likelihood."
"3B81.8,3B81,Torsion of spleen",,,Not Possible,"Torsion of the spleen typically requires imaging studies (e.g., ultrasound or CT scan) for diagnosis, which are not included in the available features. The listed hematological features do not provide sufficient information to screen for this condition."
"3B81.9,3B81,Fibrosis of spleen",,,Not Possible,"Key signals for screening fibrosis of the spleen, such as imaging studies (e.g., ultrasound, CT scan) or specific biomarkers (e.g., liver function tests indicating portal hypertension), are not available in the listed features."
"3B81.A,3B81,Perisplenitis",,,Not Possible,"Perisplenitis typically requires imaging studies (e.g., ultrasound or CT scan) to assess splenic inflammation, which are not available in the listed features. Additionally, specific clinical history and physical examination findings are crucial for diagnosis, which cannot be captured through the available laboratory measurements alone."
"3B81.B,3B81,Hypersplenism",,,Possible,"Key hematological features such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI) are available, which can help assess splenic function and potential hypersplenism. However, the absence of direct measures of splenic size or function limits the assessment's specificity."
"3B81.C,3B81,Chronic congestive splenomegaly",,,Not Possible,"Chronic congestive splenomegaly requires imaging studies (e.g., ultrasound, CT) or specific biomarkers related to splenic function and portal hypertension, which are not available in the listed features."
"3B81.Y,3B81,Other specified acquired disorders of spleen",,,Not Possible,"Key signals for assessing splenic disorders, such as imaging studies (e.g., ultrasound, CT scan) or specific laboratory tests (e.g., splenic function tests, genetic markers), are missing. The available features primarily assess blood parameters and do not provide sufficient information to screen for acquired disorders of the spleen."
"3B81.Z,3B81,""Acquired disorders of spleen, unspecified""",,,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and hemoglobin (LBXHGB), which can indicate splenic dysfunction or disorders. These features can help in screening for acquired disorders of the spleen by assessing blood cell counts and morphology, which are relevant in evaluating splenic function."
"3B8Z,3B8Z,""Diseases of spleen, unspecified""",,,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and lactate dehydrogenase (LBXSLDSI), which can indicate splenic dysfunction or disease. These features can help in screening for diseases of the spleen by assessing blood cell counts and other relevant markers."
"3C0Y,3C0Y,Other specified diseases of the blood or blood-forming organs",,,Possible,"The available features include key hematological parameters such as white blood cell count, red blood cell count, hemoglobin, hematocrit, and various white blood cell differentials (lymphocytes, monocytes, neutrophils, eosinophils, basophils). These parameters can help identify abnormalities in blood or blood-forming organs, which are essential for screening for various blood disorders."
"3C0Z,3C0Z,""Diseases of the blood or blood-forming organs, unspecified",,,Possible,"The available features include key hematological parameters such as white blood cell count, red blood cell count, hemoglobin, hematocrit, and platelet count, which are essential for screening various blood disorders. These features can help identify abnormalities indicative of diseases of the blood or blood-forming organs."
